{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}],"title":"Complete Response"},{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"22"}],"title":"Partial Response"},{"measurements":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"23"}],"title":"Stable Disease"},{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"4"}],"title":"Progressive Disease"},{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"11"}],"title":"Unknown"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"62"}],"units":"Participants"}],"description":"Complete response: Complete resolution of thrombosis, with recanalization of vessel.\n\nPartial response (PR):\n\n* Partial recanalization (if prior complete blockage)\n* Unequivocal reduction in the maximal girth\n* Unequivocal reduction in the volume, or elimination, of arterial enhancing portion\n\nProgressive disease (PD): any unequivocal, unambiguous\n\n* New enhancing tumor thrombosis\n* Increase in the volume of enhancing portion\n* Unequivocal progression of thrombosis (non-measurable disease), the increase in overall tumor burden (enhancing thrombosis) must be comparable to the increase required for the Response Evaluation Criteria in Solid Tumor 1.1 definition of PD of measurable disease (e.g. ≥ 73% increase in volume, which is similar to 20% increase in diameter, and at least a 5 mm absolute increase).\n\nStable disease:\n\n* No/small changes that do not meet the above criteria for PR or PD\n* Increase in the volume of non-enhancing thrombosis\n* New bland non-enhancing thrombosis","groups":[{"description":"400 mg sorafenib by mouth twice a day for 28-day cycle. Continue up to 5 years in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Sorafenib Alone"},{"description":"27.5 Gy to 50 Gy stereotactic body radiation therapy (SBRT) in 5 fractions 24-72 hours apart over 5-15 days followed within 1-5 days by one cycle of 200 mg sorafenib by mouth twice a day. Starting with second cycle, if tolerable, increase to 400 mg sorafenib by mouth twice a day. Continue up to 5 years in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"SBRT Followed by Sorafenib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Eligible participants who had vascular thrombosis at study entry","reportingStatus":"POSTED","timeFrame":"From randomization to last follow-up. Imaging occurs every 3 months for two years then every six months. Maximum follow-up at time of analysis was 7.6 years.","title":"Best Vascular Thrombosis Response up to the Time of Progressive Disease (if Applicable)","type":"SECONDARY","unitOfMeasure":"Participants"}